Raloxifene
- Generic Name
- Raloxifene
- Brand Names
- Evista, Optruma, Raloxifene Teva
- Drug Type
- Small Molecule
- Chemical Formula
- C28H27NO4S
- CAS Number
- 84449-90-1
- Unique Ingredient Identifier
- YX9162EO3I
- Background
Raloxifene is a second generation selective estrogen receptor modulator (SERM) that mediates anti-estrogenic effects on breast and uterine tissues, and estrogenic effects on bone, lipid metabolism, and blood coagulation. Exhibiting tissue-specific effects distinct from estradiol, raloxifene is the first of the benzothiophene group of antiestrogens to be labe...
- Indication
Indicated for the prevention and treatment of osteoporosis in postmenopausal women, as well as prevention and treatment of corticosteroid-induced bone loss.
Indicated for the reduction in the risk of invasive breast cancer in postmenopausal women with osteoporosis or postmenopausal women with a high risk for invasive breast cancer.
- Associated Conditions
- Invasive Breast Cancer, Osteoporosis, Osteoporosis caused by Glucocorticoid Treatment
- Associated Therapies
- -
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.